PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI,notes,date
35337365,Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel,"Cartron G, Fox CP, Liu FF, Kostic A, Hasskarl J, Li D, Bonner A, Zhang Y, Maloney DG, Kuruvilla J.",Exp Hematol Oncol. 2022 Mar 25;11(1):17. doi: 10.1186/s40164-022-00268-z.,Cartron G,Exp Hematol Oncol,2022,26/03/2022,PMC8953336,NA,10.1186/s40164-022-00268-z,,08/07/2022
35289710,Carfilzomib 56â€‰mg/m(2) twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison,"Weisel K, Nooka AK, Terpos E, Spencer A, Goldschmidt H, Dirnberger F, DeCosta L, Yusuf A, Kumar S.",Leuk Lymphoma. 2022 Mar 15:1-10. doi: 10.1080/10428194.2022.2047962. Online ahead of print.,Weisel K,Leuk Lymphoma,2022,15/03/2022,NA,NA,10.1080/10428194.2022.2047962,,19/07/2022
35279814,Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life,"Agirrezabal I, Brennan VK, Colaone F, Shergill S, Pereira H, Chatellier G, Vilgrain V.",Adv Ther. 2022 Mar 12. doi: 10.1007/s12325-022-02099-0. Online ahead of print.,Agirrezabal I,Adv Ther,2022,13/03/2022,NA,NA,10.1007/s12325-022-02099-0,,09/07/2022
35237351,A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577,"Pape M, Vissers PAJ, Beerepoot LV, van Berge Henegouwen MI, Lagarde SM, Mook S, Moehler M, van Laarhoven HWM, Verhoeven RHA.",Ther Adv Med Oncol. 2022 Feb 26;14:17588359221075495. doi: 10.1177/17588359221075495. eCollection 2022.,Pape M,Ther Adv Med Oncol,2022,03/03/2022,PMC8883292,NA,10.1177/17588359221075495,"Will be excluded from the review, because doesn't really compare treatment effects (+ different ""MAIC"" methodology)",19/07/2022
35232230,Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data,"Tremblay G, Groff M, Iadeluca L, Daniele P, Wilner K, Wiltshire R, Bartolome L, Usari T, Cappelleri JC, Camidge DR.",Future Oncol. 2022 Mar 2. doi: 10.2217/fon-2021-1102. Online ahead of print.,Tremblay G,Future Oncol,2022,02/03/2022,NA,NA,10.2217/fon-2021-1102,,10/07/2022
35175308,Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison,"Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C.",JAMA Ophthalmol. 2022 Feb 17:e216284. doi: 10.1001/jamaophthalmol.2021.6284. Online ahead of print.,Douglas RS,JAMA Ophthalmol,2022,17/02/2022,PMC8855315,NA,10.1001/jamaophthalmol.2021.6284,,15/07/2022
35157216,"A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib","Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K.",Adv Ther. 2022 Feb 14. doi: 10.1007/s12325-022-02054-z. Online ahead of print.,Proudman D,Adv Ther,2022,14/02/2022,NA,NA,10.1007/s12325-022-02054-z,,15/07/2022
35114819,Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis,"Pilkington H, Smith S, Roskell N, Iannazzo S.",Future Oncol. 2022 Feb 4. doi: 10.2217/fon-2021-1509. Online ahead of print.,Pilkington H,Future Oncol,2022,04/02/2022,NA,NA,10.2217/fon-2021-1509,,14/09/2022
35073727,Indirect comparison of pembrolizumab monotherapy versus nivolumabÂ +Â ipilimumab in first-line metastatic lung cancer,"Halmos B, Burke T, Kalyvas C, Insinga R, Vandormael K, Frederickson A, Piperdi B.",Immunotherapy. 2022 Apr;14(5):295-307. doi: 10.2217/imt-2021-0273. Epub 2022 Jan 25.,Halmos B,Immunotherapy,2022,25/01/2022,NA,NA,10.2217/imt-2021-0273,,18/07/2022
35068168,Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes,"Thach A, Zichlin ML, Kirson N, Yang K, Gaburo K, Pappert E, Mehta D, Williams GR.",J Comp Eff Res. 2022 Mar;11(4):285-295. doi: 10.2217/cer-2021-0178. Epub 2022 Jan 24.,Thach A,J Comp Eff Res,2022,24/01/2022,NA,NA,10.2217/cer-2021-0178,,18/07/2022
35042448,An anchored simulated treatment comparison of uptitration of amlodipine compared with a low-dose combination treatment with amlodipine 5â€‰mg/bisoprolol 5â€‰mg for patients with hypertension suboptimally controlled by amlodipine 5â€‰mg monotherapy,"Foch C, Feifel J, Gottwald-Hostalek U.",Curr Med Res Opin. 2022 Apr;38(4):587-593. doi: 10.1080/03007995.2022.2030112. Epub 2022 Feb 1.,Foch C,Curr Med Res Opin,2022,19/01/2022,NA,NA,10.1080/03007995.2022.2030112,,19/07/2022
35040693,How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison,"Ribero VA, Daigl M, MartÃ­ Y, Gorni K, Evans R, Scott DA, Mahajan A, Abrams KR, Hawkins N.",J Comp Eff Res. 2022 Apr;11(5):347-370. doi: 10.2217/cer-2021-0216. Epub 2022 Jan 18.,Ribero VA,J Comp Eff Res,2022,18/01/2022,NA,NA,10.2217/cer-2021-0216,,20/07/2022
34978255,Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison,"Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ.",Leuk Lymphoma. 2022 Jan 2:1-10. doi: 10.1080/10428194.2021.2010069. Online ahead of print.,Schuster SJ,Leuk Lymphoma,2022,03/01/2022,NA,NA,10.1080/10428194.2021.2010069,,21/07/2022
34922383,An indirect treatment comparison of semaglutide 2.0Â mg versus dulaglutide 3.0Â mg and 4.5Â mg using multilevel network meta-regression,"Lingvay I, Bauer R, Baker-Knight J, Lawson J, Pratley R.",J Clin Endocrinol Metab. 2021 Dec 18:dgab905. doi: 10.1210/clinem/dgab905. Online ahead of print.,Lingvay I,J Clin Endocrinol Metab,2021,18/12/2021,NA,NA,10.1210/clinem/dgab905,,21/07/2022
34912478,"Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours","Khan MS, Stamp E, Sammon C, Brabander T, de Herder WW, Pavel ME.",EJC Suppl. 2021 Nov 9;16:5-13. doi: 10.1016/j.ejcsup.2021.06.002. eCollection 2021 Nov.,Khan MS,EJC Suppl,2021,16/12/2021,PMC8591206,NA,10.1016/j.ejcsup.2021.06.002,,20/07/2022
34877623,Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis,"Thom H, Cheng V, Keeney E, Neary MP, Eccleston A, Zang C, Cappelleri JC, Cha A, Thyssen JP.",Dermatol Ther (Heidelb). 2022 Jan;12(1):185-194. doi: 10.1007/s13555-021-00646-1. Epub 2021 Dec 8.,Thom H,Dermatol Ther (Heidelb),2022,08/12/2021,PMC8776944,NA,10.1007/s13555-021-00646-1,,19/07/2022
34797506,Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison,"Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.",Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19.,Chowdhury S,Adv Ther,2022,19/11/2021,PMC8799579,NA,10.1007/s12325-021-01885-6,,21/07/2022
34765537,Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison,"Hampton P, Borg E, Hansen JB, Augustin M.",Psoriasis (Auckl). 2021 Nov 3;11:123-131. doi: 10.2147/PTT.S326121. eCollection 2021.,Hampton P,Psoriasis (Auckl),2021,12/11/2021,PMC8575184,NA,10.2147/PTT.S326121,,21/07/2022
34754257,Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A,"Vashi P, Batt K, Klamroth R, Mancuso ME, Majewska R, Tiede A, Mantovani LG.",J Blood Med. 2021 Nov 1;12:935-943. doi: 10.2147/JBM.S321288. eCollection 2021.,Vashi P,J Blood Med,2021,10/11/2021,PMC8570287,NA,10.2147/JBM.S321288,,21/07/2022
34754238,Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer,"Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J.",Cancer Manag Res. 2021 Nov 1;13:8179-8189. doi: 10.2147/CMAR.S325043. eCollection 2021.,Fasching PA,Cancer Manag Res,2021,10/11/2021,PMC8570288,NA,10.2147/CMAR.S325043,,22/07/2022
34751591,Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points,"Law E, Gavanji R, Walsh S, Haltner A, McTavish R, Cameron C.",J Comp Eff Res. 2022 Feb;11(2):109-120. doi: 10.2217/cer-2021-0221. Epub 2021 Nov 9.,Law E,J Comp Eff Res,2022,09/11/2021,NA,NA,10.2217/cer-2021-0221,,21/07/2022
34672224,Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20,"Mt-Isa S, Abderhalden LA, Musey L, Weiss T.",Expert Rev Vaccines. 2022 Jan;21(1):115-123. doi: 10.1080/14760584.2021.1994858. Epub 2021 Oct 27.,Mt-Isa S,Expert Rev Vaccines,2022,21/10/2021,NA,NA,10.1080/14760584.2021.1994858,,22/07/2022
34616492,Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer,"Hettle R, McCrea C, Lee CK, Davidson R.",Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639. doi: 10.1177/17588359211049639. eCollection 2021.,Hettle R,Ther Adv Med Oncol,2021,07/10/2021,PMC8488507,NA,10.1177/17588359211049639,,25/07/2022
34597975,"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, MÃ¤enpÃ¤Ã¤ J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio PÃ©rez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P.",Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28.,Vergote I,Eur J Cancer,2021,01/10/2021,NA,NA,10.1016/j.ejca.2021.08.023,"not eligible, but important to mention it somewhere",25/07/2022
34561812,DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexorâ€‰+â€‰Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma,"Prawitz T, Popat R, Suvannasankha A, Sarri G, Hughes R, Wang F, Hogea C, Ferrante SA, Gorsh B, Willson J, Kapetanakis V.",Adv Ther. 2021 Nov;38(11):5501-5518. doi: 10.1007/s12325-021-01884-7. Epub 2021 Sep 24.,Prawitz T,Adv Ther,2021,25/09/2021,PMC8523001,NA,10.1007/s12325-021-01884-7,,25/07/2022
34493319,Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma,"Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A, Zhang Y, Fox CP, Cartron G.",,Maloney DG,J Hematol Oncol,2021,08/09/2021,PMC8425084,NA,10.1186/s13045-021-01144-9,,26/07/2022
34445916,Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison,"Bhak RH, Mody-Patel N, Baver SB, Kunzweiler C, Yee CW, Sundaresan S, Swartz N, Duh MS, Krishnan S, Sarda SP.",Curr Med Res Opin. 2021 Nov;37(11):1913-1923. doi: 10.1080/03007995.2021.1971182. Epub 2021 Sep 3.,Bhak RH,Curr Med Res Opin,2021,27/08/2021,NA,NA,10.1080/03007995.2021.1971182,,25/07/2022
34372979,How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments,"Kapetanakis V, Prawitz T, Schlichting M, Ishak KJ, Phatak H, Yu T, Bharmal M.",Value Health. 2021 Aug;24(8):1137-1144. doi: 10.1016/j.jval.2021.03.004. Epub 2021 May 8.,Kapetanakis V,Value Health,2021,10/08/2021,NA,NA,10.1016/j.jval.2021.03.004,methodological,XX
34368918,Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe HaemophiliaÂ A,"Bonanad S, NÃºÃ±ez R, Poveda JL, Kurnik K, Goldmann G, Andreozzi V, Vandewalle B, Santos S.",Adv Ther. 2021 Sep;38(9):4872-4884. doi: 10.1007/s12325-021-01853-0. Epub 2021 Aug 8.,Bonanad S,Adv Ther,2021,09/08/2021,PMC8408075,NA,10.1007/s12325-021-01853-0,,24/07/2022
34286894,An indirect treatment comparison of the efficacy of semaglutide 1.0Â mg versus dulaglutide 3.0 and 4.5Â mg,"Pratley RE, Catarig AM, Lingvay I, Viljoen A, Paine A, Lawson J, Chubb B, Gorst-Rasmussen A, Miresashvili N.",Diabetes Obes Metab. 2021 Nov;23(11):2513-2520. doi: 10.1111/dom.14497. Epub 2021 Aug 9.,Pratley RE,Diabetes Obes Metab,2021,21/07/2021,NA,NA,10.1111/dom.14497,,23/07/2022
34285621,Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials,"Astermark J, Wojciechowski P, AballÃ©a S, Hakimi Z, Nazir J, Klamroth R.",J Blood Med. 2021 Jul 14;12:613-621. doi: 10.2147/JBM.S312885. eCollection 2021.,Astermark J,J Blood Med,2021,21/07/2021,PMC8286734,NA,10.2147/JBM.S312885,,25/07/2022
34277983,"A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease","Evans LM, Mellbin L, Johansen P, Lawson J, Paine A, Sandberg A.",Endocrinol Diabetes Metab. 2021 May 15;4(3):e00259. doi: 10.1002/edm2.259. eCollection 2021 Jul.,Evans LM,Endocrinol Diabetes Metab,2021,19/07/2021,PMC8279621,NA,10.1002/edm2.259,,25/07/2022
34256668,Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma,"Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA.",Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23.,Martin T,Curr Med Res Opin,2021,14/07/2021,NA,NA,10.1080/03007995.2021.1953456,,26/07/2022
34250584,Effectiveness of Radiofrequency Catheter Ablation Using Ablation Index Versus Second Generation Cryoballoon in the Treatment of Persistent Atrial Fibrillation: A Matching-Adjusted Indirect Comparison,"Hussein A, Stabile G, Dawkins K, Spin P, Goldstein L, Wei T, Velleca M, Patel L, Gupta D.",Adv Ther. 2021 Aug;38(8):4388-4402. doi: 10.1007/s12325-021-01846-z. Epub 2021 Jul 12.,Hussein A,Adv Ther,2021,12/07/2021,PMC8342373,NA,10.1007/s12325-021-01846-z,,26/07/2022
34236007,Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1,"Bischof M, Lorenzi M, Lee J, Druyts E, Balijepalli C, Dabbous O.",Curr Med Res Opin. 2021 Oct;37(10):1719-1730. doi: 10.1080/03007995.2021.1947216. Epub 2021 Jul 20.,Bischof M,Curr Med Res Opin,2021,08/07/2021,NA,NA,10.1080/03007995.2021.1947216,,26/07/2022
34067521,"Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or ""Wait and See"" Strategy?","Vitale A, Scolari F, Bertacco A, Gringeri E, D'Amico F, Bassi D, D'Amico FE, Angeli P, Burra P, Lai Q, Cillo U.",Cancers (Basel). 2021 May 17;13(10):2406. doi: 10.3390/cancers13102406.,Vitale A,Cancers (Basel),2021,02/06/2021,PMC8156031,NA,10.3390/cancers13102406,,26/07/2022
34067288,Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer,"Rapposelli IG, Casadei-Gardini A, Vivaldi C, Bartolini G, Bernardini L, Passardi A, Frassineti GL, Massa V, Cucchetti A.",Biomolecules. 2021 May 22;11(6):780. doi: 10.3390/biom11060780.,Rapposelli IG,Biomolecules,2021,02/06/2021,PMC8224606,NA,10.3390/biom11060780,,27/07/2022
34031743,Outcomes associated with the use of a new powered circular stapler for left-sided colorectal reconstructions: a propensity score matching-adjusted indirect comparison with manual circular staplers,"Sylla P, Sagar P, Johnston SS, Dwarakanathan HR, Waggoner JR, Schwiers M, Roy S.",Surg Endosc. 2022 Apr;36(4):2541-2553. doi: 10.1007/s00464-021-08542-7. Epub 2021 May 24.,Sylla P,Surg Endosc,2022,25/05/2021,PMC8921098,NA,10.1007/s00464-021-08542-7,"not eligible, PS matching",XX
34021585,"Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine","Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L'Italien G, Moren J.",Headache. 2021 Jun;61(6):906-915. doi: 10.1111/head.14128. Epub 2021 May 22.,Popoff E,Headache,2021,22/05/2021,PMC8361942,NA,10.1111/head.14128,,27/07/2022
33979770,Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis,"Cohan S, Tencer T, Arndorfer S, Zhu X, Zivkovic M, Kumar J.",Mult Scler Relat Disord. 2021 Jul;52:102972. doi: 10.1016/j.msard.2021.102972. Epub 2021 Apr 25.,Cohan S,Mult Scler Relat Disord,2021,12/05/2021,NA,NA,10.1016/j.msard.2021.102972,,27/07/2022
33970454,Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1,"Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J.",Adv Ther. 2021 Jun;38(6):3266-3280. doi: 10.1007/s12325-021-01756-0. Epub 2021 May 10.,Salles G,Adv Ther,2021,10/05/2021,PMC8189990,NA,10.1007/s12325-021-01756-0,,27/07/2022
33955326,Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naÃ¯ve chronic lymphocytic leukemia,"Davids MS, Telford C, Abhyankar S, Waweru C, Ringshausen I.",Leuk Lymphoma. 2021 Oct;62(10):2342-2351. doi: 10.1080/10428194.2021.1913144. Epub 2021 May 6.,Davids MS,Leuk Lymphoma,2021,06/05/2021,NA,NA,10.1080/10428194.2021.1913144,,27/07/2022
33896344,"Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexorâ€‰+â€‰dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma","Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S.",Leuk Lymphoma. 2021 Oct;62(10):2482-2491. doi: 10.1080/10428194.2021.1913143. Epub 2021 Apr 24.,Rodriguez-Otero P,Leuk Lymphoma,2021,26/04/2021,NA,NA,10.1080/10428194.2021.1913143,,27/07/2022
33847901,Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison,"Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.",CNS Drugs. 2021 Jul;35(7):795-804. doi: 10.1007/s40263-021-00805-0. Epub 2021 Apr 13.,Cohan S,CNS Drugs,2021,13/04/2021,PMC8310468,NA,10.1007/s40263-021-00805-0,,27/07/2022
33839603,Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison,"Halmos B, Burke T, Kalyvas C, Vandormael K, Frederickson A, Piperdi B.",Lung Cancer. 2021 May;155:175-182. doi: 10.1016/j.lungcan.2021.03.020. Epub 2021 Mar 30.,Halmos B,Lung Cancer,2021,11/04/2021,NA,NA,10.1016/j.lungcan.2021.03.020,,16/09/2022
33830214,Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis,"Wang L, Paller C, Hong H, Rosman L, De Felice A, Brawley O, Alexander GC.",J Natl Cancer Inst. 2022 Feb 7;114(2):191-202. doi: 10.1093/jnci/djab071.,Wang L,J Natl Cancer Inst,2022,08/04/2021,PMC8826526,NA,10.1093/jnci/djab071,,08/08/2022
33822328,Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoproteinâ€‰â‰¥â€‰400Â ng/mL: A Matching-Adjusted Indirect Comparison,"Trojan J, Mollon P, Daniele B, Marteau F, MartÃ­n L, Li Y, Xu Q, Piscaglia F, Zaucha R, Sarker D, Lim HY, Venerito M.",Adv Ther. 2021 May;38(5):2472-2490. doi: 10.1007/s12325-021-01700-2. Epub 2021 Apr 6.,Trojan J,Adv Ther,2021,06/04/2021,PMC8107171,NA,10.1007/s12325-021-01700-2,,07/08/2022
33818140,Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer,"Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N.",J Urol. 2021 Aug;206(2):298-307. doi: 10.1097/JU.0000000000001767. Epub 2021 Apr 5.,Halabi S,J Urol,2021,05/04/2021,NA,NA,10.1097/JU.0000000000001767,,05/08/2022
33768123,Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons,"Tremblay G, Tomaras D, Strati E, Forsythe A.",J Health Econ Outcomes Res. 2021 Feb 23;8(1):10-17. doi: 10.36469/jheor.2021.19008.,Tremblay G,J Health Econ Outcomes Res,2021,26/03/2021,PMC7983491,NA,10.36469/jheor.2021.19008,,07/08/2022
33745079,Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis,"Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A.",J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20.,Casadei-Gardini A,J Cancer Res Clin Oncol,2021,21/03/2021,NA,NA,10.1007/s00432-021-03602-w,,07/08/2022
33733983,"An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia","Muresan B, Mamolo C, Cappelleri JC, Leip E, Viqueira A, Heeg B.",Curr Med Res Opin. 2021 May;37(5):801-809. doi: 10.1080/03007995.2021.1896489. Epub 2021 Apr 2.,Muresan B,Curr Med Res Opin,2021,18/03/2021,NA,NA,10.1080/03007995.2021.1896489,,08/08/2022
33733815,Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia,"Tremblay G, Daniele P, Bell T, Chan G, Brown A, Cappelleri JC.",J Comp Eff Res. 2021 May;10(7):603-612. doi: 10.2217/cer-2020-0280. Epub 2021 Mar 18.,Tremblay G,J Comp Eff Res,2021,18/03/2021,NA,NA,10.2217/cer-2020-0280,,08/08/2022
33664606,Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials,"Klamroth R, Wojciechowski P, AballÃ©a S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD.",J Blood Med. 2021 Feb 25;12:115-122. doi: 10.2147/JBM.S288283. eCollection 2021.,Klamroth R,J Blood Med,2021,05/03/2021,PMC7921628,NA,10.2147/JBM.S288283,,08/08/2022
33638735,Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison,"Casadei-Gardini A, Tada T, Shimose S, Kumada T, Niizeki T, Cascinu S, Cucchetti A.",Target Oncol. 2021 Mar;16(2):249-254. doi: 10.1007/s11523-021-00803-8. Epub 2021 Feb 27.,Casadei-Gardini A,Target Oncol,2021,27/02/2021,NA,NA,10.1007/s11523-021-00803-8,,08/08/2022
33626934,Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer,"Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C.",J Comp Eff Res. 2021 Apr;10(6):457-467. doi: 10.2217/cer-2020-0272. Epub 2021 Feb 25.,Rugo HS,J Comp Eff Res,2021,25/02/2021,NA,NA,10.2217/cer-2020-0272,,08/08/2022
33603419,Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy,"Ghetti G, D'Avella MC, Pradelli L.",Clinicoecon Outcomes Res. 2021 Feb 10;13:121-133. doi: 10.2147/CEOR.S295605. eCollection 2021.,Ghetti G,Clinicoecon Outcomes Res,2021,19/02/2021,PMC7882423,NA,10.2147/CEOR.S295605,"No results provided for this ITC (economics analysis), therefore excluded",XX
33556898,A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(â˜†),"Tarhini AA, Toor K, Chan K, McDermott DF, Mohr P, Larkin J, Hodi FS, Lee CH, Rizzo JI, Johnson H, Moshyk A, Rao S, Kotapati S, Atkins MB.",ESMO Open. 2021 Apr;6(2):100050. doi: 10.1016/j.esmoop.2021.100050. Epub 2021 Feb 6.,Tarhini AA,ESMO Open,2021,08/02/2021,PMC7872980,NA,10.1016/j.esmoop.2021.100050,,24/08/2022
33488773,Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate,"Scott TF, Su R, Xiong K, Altincatal A, Castrillo-Viguera C, Naylor ML.",Ther Adv Neurol Disord. 2021 Jan 12;14:1756286420975916. doi: 10.1177/1756286420975916. eCollection 2021.,Scott TF,Ther Adv Neurol Disord,2021,25/01/2021,PMC7809527,NA,10.1177/1756286420975916,,09/08/2022
33442996,Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma,"Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R.",J Comp Eff Res. 2021 Apr;10(5):343-352. doi: 10.2217/cer-2020-0236. Epub 2021 Jan 14.,Parikh ND,J Comp Eff Res,2021,14/01/2021,NA,NA,10.2217/cer-2020-0236,,09/08/2022
33377987,Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with HaemophiliaÂ A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison,"Hakimi Z, Santagostino E, Postma MJ, Nazir J.",Adv Ther. 2021 Feb;38(2):1263-1274. doi: 10.1007/s12325-020-01599-1. Epub 2020 Dec 30.,Hakimi Z,Adv Ther,2021,30/12/2020,PMC7889532,NA,10.1007/s12325-020-01599-1,,09/08/2022
33291810,A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS â‰¥1% Metastatic NSCLC,"Halmos B, Burke T, Kalyvas C, Insinga R, Vandormael K, Frederickson A, Piperdi B.",Cancers (Basel). 2020 Dec 4;12(12):3648. doi: 10.3390/cancers12123648.,Halmos B,Cancers (Basel),2020,09/12/2020,PMC7762014,NA,10.3390/cancers12123648,,09/08/2022
33244703,A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis,"Edwards CJ, Sawant R, Garg V, Du EX, Friedman A, Betts KA.",Rheumatol Ther. 2021 Mar;8(1):167-181. doi: 10.1007/s40744-020-00257-w. Epub 2020 Nov 26.,Edwards CJ,Rheumatol Ther,2021,27/11/2020,PMC7991064,NA,10.1007/s40744-020-00257-w,,09/08/2022
33228440,Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison,"Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai EK, Goldschmidt H, Bertsch U, Vanquickelberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P.",Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24.,Moreau P,Immunotherapy,2021,24/11/2020,NA,NA,10.2217/imt-2020-0266,,24/08/2022
32969597,Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study,"Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, FoÃ  R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group.",Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.,Cuneo A,Cancer Med,2020,24/09/2020,PMC7666748,NA,10.1002/cam4.3470,Not a MAIC,XX
32892660,Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy,"Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H.",Expert Opin Pharmacother. 2021 Jan;22(1):121-129. doi: 10.1080/14656566.2020.1811850. Epub 2020 Sep 7.,Gorevic P,Expert Opin Pharmacother,2021,07/09/2020,NA,NA,10.1080/14656566.2020.1811850,,09/08/2022
32648475,Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer,"Chu P, Antoniou M, Bhutani MK, Aziez A, Daigl M.",J Comp Eff Res. 2020 Aug;9(12):861-876. doi: 10.2217/cer-2020-0063. Epub 2020 Jul 10.,Chu P,J Comp Eff Res,2020,11/07/2020,NA,NA,10.2217/cer-2020-0063,,24/08/2022
32602756,Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia,"Ma Q, Zhang J, O'Brien E, Martin AL, Agostinho AC.",J Comp Eff Res. 2020 Aug;9(12):849-860. doi: 10.2217/cer-2020-0069. Epub 2020 Jun 30.,Ma Q,J Comp Eff Res,2020,01/07/2020,NA,NA,10.2217/cer-2020-0069,,25/08/2022
32561336,"Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma","Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL.",Biol Blood Marrow Transplant. 2020 Sep;26(9):1581-1588. doi: 10.1016/j.bbmt.2020.06.008. Epub 2020 Jun 17.,Oluwole OO,Biol Blood Marrow Transplant,2020,21/06/2020,NA,NA,10.1016/j.bbmt.2020.06.008,,12/08/2022
32424805,Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma,"Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK.",Adv Ther. 2020 Jun;37(6):2678-2695. doi: 10.1007/s12325-020-01378-y. Epub 2020 May 18.,Kelley RK,Adv Ther,2020,20/05/2020,PMC7467441,NA,10.1007/s12325-020-01378-y,,12/08/2022
32371431,"Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naÃ¯ve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison","Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F, Kannowski CL, Nicolay C, Kadziola Z, De La Torre I, Fleischmann R.",RMD Open. 2020 Apr;6(1):e001131. doi: 10.1136/rmdopen-2019-001131.,Fautrel B,RMD Open,2020,07/05/2020,PMC7299519,NA,10.1136/rmdopen-2019-001131,,12/08/2022
32299269,Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12,"Gottlieb AB, Saure D, Wilhelm S, Dossenbach M, Schuster C, Smith SD, Ramot Y, ThaÃ§i D.",J Dermatolog Treat. 2022 Feb;33(1):54-61. doi: 10.1080/09546634.2020.1747592. Epub 2020 Apr 17.,Gottlieb AB,J Dermatolog Treat,2022,18/04/2020,NA,NA,10.1080/09546634.2020.1747592,,25/08/2022
32222903,Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2Â Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison,"Ohji M, Lanzetta P, Korobelnik JF, Wojciechowski P, Taieb V, Deschaseaux C, Janer D, Tuckmantel C.",Adv Ther. 2020 May;37(5):2184-2198. doi: 10.1007/s12325-020-01298-x. Epub 2020 Mar 28.,Ohji M,Adv Ther,2020,31/03/2020,PMC7467478,NA,10.1007/s12325-020-01298-x,,12/08/2022
32220214,Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis,"Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Rouyrre N, Dahlke F, Adlard N.",Curr Med Res Opin. 2020 Jul;36(7):1157-1166. doi: 10.1080/03007995.2020.1747999. Epub 2020 Apr 14.,Samjoo IA,Curr Med Res Opin,2020,30/03/2020,NA,NA,10.1080/03007995.2020.1747999,,31/08/2022
31985301,Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis,"Wu JJ, Hansen JB, Patel DS, Nyholm N, Veverka KA, Swensen AR.",J Med Econ. 2020 Jun;23(6):641-649. doi: 10.1080/13696998.2020.1722139. Epub 2020 Mar 2.,Wu JJ,J Med Econ,2020,28/01/2020,NA,NA,10.1080/13696998.2020.1722139,,13/08/2022
31948278,Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis,"Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J.",J Comp Eff Res. 2020 Mar;9(4):275-285. doi: 10.2217/cer-2019-0169. Epub 2020 Jan 17.,Swallow E,J Comp Eff Res,2020,18/01/2020,NA,NA,10.2217/cer-2019-0169,,12/08/2022
31943429,Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics,"Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X.",Clin Exp Allergy. 2020 Apr;50(4):442-452. doi: 10.1111/cea.13561. Epub 2020 Mar 20.,Bourdin A,Clin Exp Allergy,2020,17/01/2020,PMC7204869,NA,10.1111/cea.13561,,15/08/2022
31940225,Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries,"Balak DMW, Carrascosa JM, Gregoriou S, Calzavara-Pinton P, Bewley A, Antunes J, Nyeland ME, Viola MG, Sawyer LM, Becla L.",J Dermatolog Treat. 2021 Nov;32(7):701-708. doi: 10.1080/09546634.2019.1707754. Epub 2020 Mar 6.,Balak DMW,J Dermatolog Treat,2021,16/01/2020,NA,NA,10.1080/09546634.2019.1707754,Reusing another MAIC,XX
31872771,Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer,"Chau I, Ayers D, Goring S, Cope S, Korytowsky B, Abraham P.",J Comp Eff Res. 2020 Jan;9(2):103-114. doi: 10.2217/cer-2019-0145. Epub 2019 Dec 24.,Chau I,J Comp Eff Res,2020,25/12/2019,NA,NA,10.2217/cer-2019-0145,,01/09/2022
31865547,Treatment of Atrial Fibrillation Using Ablation Index-Guided Contact Force Ablation: A Matching-Adjusted Indirect Comparison to Cryoballoon Ablation,"Hussein A, Gupta D, De Potter T, Spin P, Eaton K, Goldstein L, Velleca M, Costa G, Grima D, Patel L, Stabile G.",Adv Ther. 2020 Feb;37(2):785-799. doi: 10.1007/s12325-019-01173-4. Epub 2019 Dec 21.,Hussein A,Adv Ther,2020,23/12/2019,PMC7004430,NA,10.1007/s12325-019-01173-4,,15/08/2022
31813087,Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer,"Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.",Adv Ther. 2020 Jan;37(1):512-526. doi: 10.1007/s12325-019-01157-4. Epub 2019 Dec 7.,Chowdhury S,Adv Ther,2020,09/12/2019,NA,NA,10.1007/s12325-019-01157-4,,16/08/2022
31813086,Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer,"Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.",Adv Ther. 2020 Jan;37(1):501-511. doi: 10.1007/s12325-019-01156-5. Epub 2019 Dec 7.,Chowdhury S,Adv Ther,2020,09/12/2019,PMC6979453,NA,10.1007/s12325-019-01156-5,,16/08/2022
31699438,Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma,"Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z.",Clin Ther. 2019 Nov;41(11):2357-2379.e1. doi: 10.1016/j.clinthera.2019.09.012. Epub 2019 Nov 4.,Telford C,Clin Ther,2019,09/11/2019,NA,NA,10.1016/j.clinthera.2019.09.012,,17/08/2022
31686561,"The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison","Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J.",Leuk Lymphoma. 2020 Mar;61(3):680-690. doi: 10.1080/10428194.2019.1675881. Epub 2019 Nov 5.,Mateos MV,Leuk Lymphoma,2020,06/11/2019,NA,NA,10.1080/10428194.2019.1675881,,17/08/2022
31686559,"A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)","Dimopoulos MA, Cavo M, Mateos MV, Facon T, Heeg B, van Beekhuizen S, Gebregergish SB, Nair S, Pisini M, Lam A, Slavcev M.",Leuk Lymphoma. 2020 Mar;61(3):714-720. doi: 10.1080/10428194.2019.1682571. Epub 2019 Nov 5.,Dimopoulos MA,Leuk Lymphoma,2020,06/11/2019,NA,NA,10.1080/10428194.2019.1682571,,18/08/2022
31642037,Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression,"Cooper MC, Kilvert HS, Hodgkins P, Roskell NS, Eldar-Lissai A.",CNS Drugs. 2019 Oct;33(10):1039-1052. doi: 10.1007/s40263-019-00672-w.,Cooper MC,CNS Drugs,2019,24/10/2019,PMC6825025,NA,10.1007/s40263-019-00672-w,,18/08/2022
31640435,Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials,"Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H, Campioni M, Szabo Z, Dimopoulos M.",Leuk Lymphoma. 2020 Jan;61(1):37-46. doi: 10.1080/10428194.2019.1648806. Epub 2019 Oct 22.,Weisel K,Leuk Lymphoma,2020,24/10/2019,NA,NA,10.1080/10428194.2019.1648806,,18/08/2022
31564931,"Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons","Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A.",Clinicoecon Outcomes Res. 2019 Sep 6;11:551-565. doi: 10.2147/CEOR.S203482. eCollection 2019.,Tremblay G,Clinicoecon Outcomes Res,2019,01/10/2019,PMC6735653,NA,10.2147/CEOR.S203482,,18/08/2022
31417326,Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A,"Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R.",J Blood Med. 2019 Jun 20;10:147-159. doi: 10.2147/JBM.S206806. eCollection 2019.,Batt K,J Blood Med,2019,17/08/2019,PMC6592019,NA,10.2147/JBM.S206806,,18/08/2022
31412011,"Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy","Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P, de Wit R.",Eur Urol Oncol. 2019 Sep;2(5):565-571. doi: 10.1016/j.euo.2018.09.009. Epub 2018 Nov 8.,Patterson K,Eur Urol Oncol,2019,15/08/2019,NA,NA,10.1016/j.euo.2018.09.009,,18/08/2022
31364979,Comparative effectiveness of secukinumab and etanercept in biologic-naÃ¯ve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison,"Mease P, Choy E, Nash P, Kalyvas C, Hunger M, Pricop L, Gandhi KK, Jugl SM, Thom H.",Eur J Rheumatol. 2018 Jul 1;6(3):113-121. doi: 10.5152/eurjrheum.2019.19057. Print 2019 Jul.,Mease P,Eur J Rheumatol,2018,01/08/2019,PMC6668637,NA,10.5152/eurjrheum.2019.19057,,18/08/2022
31218655,Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States,"Delea TE, Zhang X, Amdahl J, Boyko D, Dirnberger F, Campioni M, Cong Z.",Pharmacoeconomics. 2019 Sep;37(9):1177-1193. doi: 10.1007/s40273-019-00812-6.,Delea TE,Pharmacoeconomics,2019,21/06/2019,PMC6830399,NA,10.1007/s40273-019-00812-6,"Will be excluded because doesn't report any results, used within an economics analysis",18/08/2022
31140123,Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia,"Proskorovsky I, Su Y, Fahrbach K, Vandendries E, PagÃ© V, Onyekwere U, Wang Y, Cappelleri JC, Stelljes M.",Adv Ther. 2019 Aug;36(8):2147-2160. doi: 10.1007/s12325-019-00991-w. Epub 2019 May 28.,Proskorovsky I,Adv Ther,2019,30/05/2019,PMC6822860,NA,10.1007/s12325-019-00991-w,,18/08/2022
30964361,"Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia","Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B.",Curr Med Res Opin. 2019 Sep;35(9):1615-1622. doi: 10.1080/03007995.2019.1605239. Epub 2019 May 15.,Cortes JE,Curr Med Res Opin,2019,10/04/2019,NA,NA,10.1080/03007995.2019.1605239,,19/08/2022
30852924,Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison,"Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, Rao S, McDermott DF.",Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.,Atkins MB,Immunotherapy,2019,12/03/2019,NA,NA,10.2217/imt-2018-0208,,19/08/2022
30806520,Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis,"Strand V, McInnes I, Mease P, Nash P, Thom H, Kalyvas C, Hunger M, Gandhi K, Pricop L, Jugl S, Choy E.",J Comp Eff Res. 2019 May;8(7):497-510. doi: 10.2217/cer-2018-0141. Epub 2019 Feb 26.,Strand V,J Comp Eff Res,2019,27/02/2019,NA,NA,10.2217/cer-2018-0141,,19/08/2022
30786783,Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches,"Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL.",Curr Med Res Opin. 2019 Aug;35(8):1371-1378. doi: 10.1080/03007995.2019.1585779. Epub 2019 Mar 29.,Berardi A,Curr Med Res Opin,2019,22/02/2019,NA,NA,10.1080/03007995.2019.1585779,,23/08/2022
30758745,Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia,"Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S.",Adv Ther. 2019 Apr;36(4):950-961. doi: 10.1007/s12325-019-0873-7. Epub 2019 Feb 13.,Song J,Adv Ther,2019,14/02/2019,PMC6824351,NA,10.1007/s12325-019-0873-7,,23/08/2022
30567533,"Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses","Proskorovsky I, Benedict A, Negrier S, Bargo D, Sandin R, Ramaswamy K, Desai J, Cappelleri JC, Larkin J.",BMC Cancer. 2018 Dec 19;18(1):1271. doi: 10.1186/s12885-018-5157-0.,Proskorovsky I,BMC Cancer,2018,21/12/2018,PMC6300002,NA,10.1186/s12885-018-5157-0,,23/08/2022
30472749,"Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison","Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J.",J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1107-1115. doi: 10.1111/jdv.15369. Epub 2019 Mar 19.,Bewley AP,J Eur Acad Dermatol Venereol,2019,26/11/2018,PMC6766948,NA,10.1111/jdv.15369,,23/08/2022
30388073,Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison,"Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.",Eur J Rheumatol. 2018 Dec;5(4):216-223. doi: 10.5152/eurjrheum.2018.18162. Epub 2018 Oct 30.,Maksymowych WP,Eur J Rheumatol,2018,03/11/2018,PMC6267743,NA,10.5152/eurjrheum.2018.18162,,23/08/2022
30362839,Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls,"Li J, Knoll S, Bocharova I, Tang W, Signorovitch J.",Curr Med Res Opin. 2019 Jan;35(1):105-111. doi: 10.1080/03007995.2018.1541443. Epub 2018 Nov 15.,Li J,Curr Med Res Opin,2019,27/10/2018,NA,NA,10.1080/03007995.2018.1541443,,24/08/2022
30314617,Focused Ultrasound Thalamotomy and Other Interventions for Medication-Refractory Essential Tremor: An Indirect Comparison of Short-Term Impact on Health-Related Quality of Life,"Langford BE, Ridley CJA, Beale RC, Caseby SCL, Marsh WJ, Richard L.",Value Health. 2018 Oct;21(10):1168-1175. doi: 10.1016/j.jval.2018.03.015. Epub 2018 Jun 28.,Langford BE,Value Health,2018,14/10/2018,NA,NA,10.1016/j.jval.2018.03.015,,24/08/2022
30309978,Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review,"Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X.",Eur Respir J. 2018 Nov 29;52(5):1801393. doi: 10.1183/13993003.01393-2018. Print 2018 Nov.,Bourdin A,Eur Respir J,2018,13/10/2018,PMC6277255,NA,10.1183/13993003.01393-2018,,24/08/2022
30286627,Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer,"Reckamp K, Lin HM, Huang J, Proskorovsky I, Reichmann W, Krotneva S, Kerstein D, Huang H, Lee J.",Curr Med Res Opin. 2019 Apr;35(4):569-576. doi: 10.1080/03007995.2018.1520696. Epub 2018 Oct 5.,Reckamp K,Curr Med Res Opin,2019,06/10/2018,NA,NA,10.1080/03007995.2018.1520696,,01/09/2022
30168349,Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison,"Ishak KJ, Rael M, Hicks M, Mittal S, Eatock M, Valle JW.",J Comp Eff Res. 2018 Oct;7(10):947-958. doi: 10.2217/cer-2018-0020. Epub 2018 Aug 31.,Ishak KJ,J Comp Eff Res,2018,01/09/2018,NA,NA,10.2217/cer-2018-0020,,01/09/2022
30086654,Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison,"Levy MY, McGarry LJ, Huang H, Lustgarten S, Chiroli S, Iannazzo S.",Curr Med Res Opin. 2019 Mar;35(3):479-487. doi: 10.1080/03007995.2018.1510225. Epub 2018 Aug 24.,Levy MY,Curr Med Res Opin,2019,09/08/2018,NA,NA,10.1080/03007995.2018.1510225,,02/09/2022
30052894,Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS,"Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.",Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160.,Camm AJ,Europace,2019,28/07/2018,NA,NA,10.1093/europace/euy160,,02/09/2022
29949047,Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis,"Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J.",Adv Ther. 2018 Jul;35(7):1035-1048. doi: 10.1007/s12325-018-0734-9. Epub 2018 Jun 15.,Li J,Adv Ther,2018,28/06/2018,NA,NA,10.1007/s12325-018-0734-9,,02/09/2022
29861642,"Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer","Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M.",Cancer Manag Res. 2018 May 22;10:1319-1327. doi: 10.2147/CMAR.S163478. eCollection 2018.,Tremblay G,Cancer Manag Res,2018,05/06/2018,PMC5968783,NA,10.2147/CMAR.S163478,,02/09/2022
29764245,Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison,"Keeping S, Wu E, Chan K, Mojebi A, Ferrante SA, Balakumaran A.",Expert Rev Hematol. 2018 Jun;11(6):503-511. doi: 10.1080/17474086.2018.1475226. Epub 2018 May 23.,Keeping S,Expert Rev Hematol,2018,17/05/2018,NA,NA,10.1080/17474086.2018.1475226,,02/09/2022
29605841,Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison,"Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.",Rheumatol Ther. 2018 Jun;5(1):99-122. doi: 10.1007/s40744-018-0106-6. Epub 2018 Mar 31.,Nash P,Rheumatol Ther,2018,02/04/2018,PMC5935619,NA,10.1007/s40744-018-0106-6,,04/09/2022
29570121,Progression of Adjacent-level Degeneration After Lumbar Total Disc Replacement: Results of a Post-hoc Analysis of Patients With Available Radiographs From a Prospective Study With 5-year Follow-up,"Zigler JE, Blumenthal SL, Guyer RD, Ohnmeiss DD, Patel L.",Spine (Phila Pa 1976). 2018 Oct 15;43(20):1395-1400. doi: 10.1097/BRS.0000000000002647.,Zigler JE,Spine (Phila Pa 1976),2018,24/03/2018,PMC6203419,NA,10.1097/BRS.0000000000002647,,05/09/2022
29458286,Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States,"Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K.",J Med Econ. 2018 Jun;21(6):577-586. doi: 10.1080/13696998.2018.1443111. Epub 2018 Mar 12.,Zhou ZY,J Med Econ,2018,21/02/2018,NA,NA,10.1080/13696998.2018.1443111,,05/09/2022
29192016,Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison,"Van Sanden S, Ito T, Diels J, Vogel M, Belch A, Oriol A.",Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.,Van Sanden S,Oncologist,2018,02/12/2017,PMC5905688,NA,10.1634/theoncologist.2017-0103,,06/09/2022
29171861,Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab,"Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, Schacht A, Mallbris L, Nast A.",Br J Dermatol. 2018 May;178(5):1064-1071. doi: 10.1111/bjd.16140. Epub 2018 Mar 1.,Warren RB,Br J Dermatol,2018,25/11/2017,NA,NA,10.1111/bjd.16140,,06/09/2022
28967482,"Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States","Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S.",Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.,Pelligra CG,Clin Ther,2017,03/10/2017,NA,NA,10.1016/j.clinthera.2017.08.010,,07/09/2022
28762213,Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison,"Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.",Rheumatol Ther. 2017 Dec;4(2):349-362. doi: 10.1007/s40744-017-0070-6. Epub 2017 Jul 31.,Strand V,Rheumatol Ther,2017,02/08/2017,PMC5696282,NA,10.1007/s40744-017-0070-6,,07/09/2022
28607774,A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma,"Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D.",J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760. Epub 2017 May 21.,Odom D,J Skin Cancer,2017,14/06/2017,PMC5457749,NA,10.1155/2017/6121760,,07/09/2022
28573505,Comparative Efficacy of Ibrutinib Versus ObinutuzumabÂ +Â Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison,"Van Sanden S, Baculea S, Diels J, Cote S.",Adv Ther. 2017 Jul;34(7):1650-1661. doi: 10.1007/s12325-017-0564-1. Epub 2017 Jun 1.,Van Sanden S,Adv Ther,2017,03/06/2017,PMC5504213,NA,10.1007/s12325-017-0564-1,,07/09/2022
28350241,Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison,"Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.",J Comp Eff Res. 2017 Jun;6(4):313-323. doi: 10.2217/cer-2016-0085. Epub 2017 Mar 28.,Chan A,J Comp Eff Res,2017,29/03/2017,NA,NA,10.2217/cer-2016-0085,,07/09/2022
28265459,Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease,"Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.",J Clin Mov Disord. 2017 Mar 1;4:3. doi: 10.1186/s40734-017-0051-5. eCollection 2017.,Claassen DO,J Clin Mov Disord,2017,08/03/2017,PMC5331691,NA,10.1186/s40734-017-0051-5,,07/09/2022
27733070,Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis,"Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL.",Curr Med Res Opin. 2017 Feb;33(2):175-183. doi: 10.1080/03007995.2016.1248380. Epub 2016 Nov 10.,Fox RJ,Curr Med Res Opin,2017,14/10/2016,NA,NA,10.1080/03007995.2016.1248380,,07/09/2022
27550239,Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data,"Majer I, van de Wetering G, Polanyi Z, Krishna A, Gray E, Roy A.",Appl Health Econ Health Policy. 2017 Feb;15(1):45-55. doi: 10.1007/s40258-016-0271-0.,Majer I,Appl Health Econ Health Policy,2017,24/08/2016,NA,NA,10.1007/s40258-016-0271-0,,09/09/2022
27445511,Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A,"Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.",J Blood Med. 2016 Jul 4;7:129-37. doi: 10.2147/JBM.S104074. eCollection 2016.,Pocoski J,J Blood Med,2016,23/07/2016,PMC4938137,NA,10.2147/JBM.S104074,,09/09/2022
27288979,Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls,"Tan DS, AraÃºjo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.",J Thorac Oncol. 2016 Sep;11(9):1550-7. doi: 10.1016/j.jtho.2016.05.029. Epub 2016 Jun 8.,Tan DS,J Thorac Oncol,2016,12/06/2016,NA,NA,10.1016/j.jtho.2016.05.029,,09/09/2022
26839044,Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison,"Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.",Clin Ther. 2016 Feb;38(2):404-12. doi: 10.1016/j.clinthera.2015.12.017. Epub 2016 Feb 3.,Swallow E,Clin Ther,2016,04/02/2016,NA,NA,10.1016/j.clinthera.2015.12.017,,09/09/2022
26793987,Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison,"Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.",J Comp Eff Res. 2016 May;5(3):273-9. doi: 10.2217/cer.15.69. Epub 2016 Jan 21.,Swallow E,J Comp Eff Res,2016,23/01/2016,NA,NA,10.2217/cer.15.69,,09/09/2022
26602976,An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed,"Sherman S, Amzal B, Calvo E, Wang X, Park J, Liu Z, Lin C, Casciano R.",Clin Ther. 2015 Oct 22:S0149-2918(15)01144-3. doi: 10.1016/j.clinthera.2015.09.013. Online ahead of print.,Sherman S,Clin Ther,2015,26/11/2015,NA,NA,10.1016/j.clinthera.2015.09.013,,11/09/2022
26455472,"Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology","Van Sanden S, Pisini M, Duchesne I, Mehnert A, Belsey J.",Curr Med Res Opin. 2016;32(1):147-54. doi: 10.1185/03007995.2015.1106934. Epub 2015 Oct 29.,Van Sanden S,Curr Med Res Opin,2016,13/10/2015,NA,NA,10.1185/03007995.2015.1106934,,13/09/2022
26390233,Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison,"Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.",J Comp Eff Res. 2016 Mar;5(2):129-39. doi: 10.2217/cer.15.49. Epub 2015 Sep 21.,Swallow E,J Comp Eff Res,2016,22/09/2015,NA,NA,10.2217/cer.15.49,,13/09/2022
26159375,Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection,"Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.",J Comp Eff Res. 2015 Nov;4(6):593-605. doi: 10.2217/cer.15.33. Epub 2015 Jul 10.,Signorovitch JE,J Comp Eff Res,2015,11/07/2015,NA,NA,10.2217/cer.15.33,,13/09/2022
27202160,Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy NaÃ¯ve Patients,"Dearden L, Majer I, Heeg B, Liwing J, Sandstrom K, Diels J.",Value Health. 2014 Nov;17(7):A616. doi: 10.1016/j.jval.2014.08.2170. Epub 2014 Oct 26.,Dearden L,Value Health,2014,21/05/2016,NA,NA,10.1016/j.jval.2014.08.2170,abstract only,XX
27202151,"Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL), Using Matching Adjusted Indirect Comparison","Tongbram V, Sengupta N, Gaudig M, Sidhu M, Exuzides A, Colby C, Sanden SV, McGovern A.",Value Health. 2014 Nov;17(7):A614-5. doi: 10.1016/j.jval.2014.08.2163. Epub 2014 Oct 26.,Tongbram V,Value Health,2014,21/05/2016,NA,NA,10.1016/j.jval.2014.08.2163,abstract only,XX
25356603,One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison,"Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ.",Curr Med Res Opin. 2015 Feb;31(2):315-22. doi: 10.1185/03007995.2014.977992. Epub 2014 Nov 7.,Signorovitch JE,Curr Med Res Opin,2015,31/10/2014,NA,NA,10.1185/03007995.2014.977992,,14/09/2022
24314093,Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison,"Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.",Exp Hematol Oncol. 2013 Dec 6;2(1):32. doi: 10.1186/2162-3619-2-32.,Signorovitch J,Exp Hematol Oncol,2013,10/12/2013,PMC4175512,NA,10.1186/2162-3619-2-32,,14/09/2022
23975660,Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology,"Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.",CNS Drugs. 2013 Nov;27(11):943-53. doi: 10.1007/s40263-013-0102-x.,Sikirica V,CNS Drugs,2013,27/08/2013,PMC3824845,NA,10.1007/s40263-013-0102-x,,15/09/2022
23339434,Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis,"Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.",J Med Econ. 2013;16(4):479-89. doi: 10.3111/13696998.2013.768530. Epub 2013 Feb 7.,Kirson NY,J Med Econ,2013,24/01/2013,NA,NA,10.3111/13696998.2013.768530,,15/09/2022
23113551,Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison,"Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.",Appl Health Econ Health Policy. 2012 Nov 1;10(6):381-95. doi: 10.1007/BF03261873.,Erder MH,Appl Health Econ Health Policy,2012,02/11/2012,NA,NA,10.1007/BF03261873,,15/09/2022
21819162,Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials,"Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.",Clin Drug Investig. 2011;31(9):665-74. doi: 10.2165/11592490-000000000-00000.,Signorovitch JE,Clin Drug Investig,2011,09/08/2011,NA,NA,10.2165/11592490-000000000-00000,,16/09/2022
21585706,Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes,"Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.",Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x.,Chang GC,Asia Pac J Clin Oncol,2011,19/05/2011,NA,NA,10.1111/j.1743-7563.2011.01400.x,,16/09/2022
21524239,Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials,"Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.",Curr Med Res Opin. 2011 Jun;27(6):1263-71. doi: 10.1185/03007995.2011.576238. Epub 2011 Apr 28.,Signorovitch JE,Curr Med Res Opin,2011,29/04/2011,NA,NA,10.1185/03007995.2011.576238,,16/09/2022
34991104,"A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma","Chan A, Dang C, Wisniewski J, Weng X, Hynson E, Zhong L, Wilson L.",Am J Clin Oncol. 2022 Feb 1;45(2):66-73. doi: 10.1097/COC.0000000000000884.,Chan A,Am J Clin Oncol,2022,06/01/2022,NA,NA,10.1097/COC.0000000000000884,"To be excluded: say they do a MAIC but from the description of their methodology and lack of references to the appropriate literature, it is not clear that they actually are doing one",16/09/2022
34080140,The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden,"Nilsson FOL, Asanin ST, Masters ET, Iadeluca L, Almond C, Cooper M, Smith S.",Pharmacoeconomics. 2021 Aug;39(8):941-952. doi: 10.1007/s40273-021-01015-8. Epub 2021 Jun 3.,Nilsson FOL,Pharmacoeconomics,2021,03/06/2021,PMC8298221,NA,10.1007/s40273-021-01015-8,,16/09/2022
33052055,Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma,"Keeping S, Xu Y, Chen CI, Cope S, Mojebi A, Kuznik A, Konidaris G, Ayers D, Sasane M, Allen R, Huynh TM, Popoff E, Freeman M, Andria ML, Fury MG, Singh K, Stockfleth E, Challapalli A, Schmults CD.",Future Oncol. 2021 Feb;17(5):611-627. doi: 10.2217/fon-2020-0823. Epub 2020 Oct 14.,Keeping S,Future Oncol,2021,14/10/2020,NA,NA,10.2217/fon-2020-0823,,16/09/2022
32826180,Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States,"Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R.",Clin Genitourin Cancer. 2021 Feb;19(1):e17-e30. doi: 10.1016/j.clgc.2020.07.006. Epub 2020 Jul 16.,Hale O,Clin Genitourin Cancer,2021,23/08/2020,NA,NA,10.1016/j.clgc.2020.07.006,,16/09/2022
32550696,Rosacea Treatment Satisfaction: Matching Adjusted Indirect Treatment Comparison Analysis of Metronidazole Gel or Cream vs Azelaic Acid Foam,"Williamson T, LaRose A, Cameron J, Lott J, Eaddy M, Hopson S, Shih HC, Tennant LT.",J Drugs Dermatol. 2020 Mar 1;19(3):295-304.,Williamson T,J Drugs Dermatol,2020,19/06/2020,NA,NA,10.36849/JDD.2020.3679,"Not using aggregated data, using only IPD",XX
30547369,Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal,"Ren S, Squires H, Hock E, Kaltenthaler E, Rawdin A, Alifrangis C.",Pharmacoeconomics. 2019 Sep;37(9):1073-1080. doi: 10.1007/s40273-018-0750-2.,Ren S,Pharmacoeconomics,2019,15/12/2018,NA,NA,10.1007/s40273-018-0750-2,"health technology approval mentioning results from a STC, but not conducting one",XX
25414048,No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis,"Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G.",Adv Ther. 2014 Nov;31(11):1134-54. doi: 10.1007/s12325-014-0167-z. Epub 2014 Nov 21.,Nixon R,Adv Ther,2014,22/11/2014,PMC4245493,,10.1007/s12325-014-0167-z,"Discarded during articles selection process, but included after seeing a reference to it in the literature",13/09/2022
